Bardin Hill Management Partners’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Bardin Hill Management Partners’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-90,508	Closed	-$6.81M	–	105
2022 Q2	$6.81M	Buy	+90,508	New	+$4.02M	1.78%	16

Bardin Hill Management Partners's TPTX Position: Q3 2022 in Review

Bardin Hill Management Partners sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 90,508 shares — an estimated $6.81M sold.

Bardin Hill Management Partners first reported a position in TPTX in Q2 2022 and held it in 1 quarter. The position peaked at $6.81M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Bardin Hill Management Partners reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Bardin Hill Management Partners sold 90,508 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $6.81M.
Bardin Hill Management Partners first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
Bardin Hill Management Partners's Turning Point Therapeutics, Inc. Common Stock position peaked at $6.81M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Bardin Hill Management Partners's 13F filing for Q3 2022, filed 14 Nov 2022.